Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

25.34 +0.06 (+0.24%)
Streaming Delayed Price Updated: 2:18 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 Next >
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
Via Investor Brand Network
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
Via Investor Brand Network
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
From Deciphera Pharmaceuticals
Via Business Wire
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 3, 2021
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
From Deciphera Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.